Abstract
This study investigates the association of CRP (C-reactive protein) single-nucleotide polymorphisms (SNPs) with plasma CRP levels and radiographic severity in African Americans with early and established rheumatoid arthritis (RA). Using a cross-sectional case-only design, CRP SNPs were genotyped in two independent sets of African Americans with RA: Consortium for the Longitudinal Evaluation of African Americans with RA (CLEAR 1) and CLEAR 2. Radiographic data and CRP measurements were available for 294 individuals from CLEAR 1 (median (interquartile range (IQR) 25-75) disease duration of 1 (0.6-1.6) year) and in 407 persons from CLEAR 2 (median (IQR 25-75) disease duration of 8.9 (3.5-17.7) years). In CLEAR 1, in adjusted models, the minor allele of rs2808630 was associated with total radiographic score (incident rate ratio 0.37 (95% confidence interval (CI) 0.19-0.74), P-value=0.0051). In CLEAR 2, the minor allele of rs3093062 was associated with increased plasma CRP levels (P-value=0.002). For each rs3093062 minor allele, the plasma CRP increased by 1.51 (95% CI 1.15-1.95) mg dl-1 when all the other covariates remained constant. These findings have important implications for assessment of the risk of joint damage in African Americans with RA.
| Original language | English |
|---|---|
| Pages (from-to) | 446-451 |
| Number of pages | 6 |
| Journal | Genes and Immunity |
| Volume | 16 |
| Issue number | 7 |
| DOIs | |
| State | Published - Oct 1 2015 |
Bibliographical note
Publisher Copyright:© 2015 Macmillan Publishers Limited All rights reserved.
Funding
The work reported in the manuscript was supported by the UAB Center for Clinical and Translational Studies (grant number 5UL1 RR025777-03 from the NIH National Center for Research Resources; NIH N01 AR-6-2278—Continuation of the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry); NIH 2P60 AR048095-06 Multidisciplinary Clinical Research Center Project 3: Predictors of Rheumatoid Arthritis Severity in African Americans (SLB); and NIH K23 AR62100 (MID), NIH K01 AR060848 (RJR) and an American College of Rheumatology Research and Education Foundation Within Our Reach Rheumatoid Arthritis Translational Research Grant (SLB). The study sponsors were not involved in the study design, the collection, analysis and interpretation data, the writing of the report or in the decision to submit the paper for publication. We acknowledge the contribution of the following CLEAR Investigators: Beth L Jonas, MD, University of North Carolina, Chapel Hill, NC, USA; Edwin A Smith, MD, Medical University of South Carolina, Charleston, SC, USA; Richard D Brasington, Jr, MD, Washington University, St. Louis, MO, USA for providing access to data for this study. We thank Peter K Gregersen, MD at The Feinstein Institute for Medical Research, Manhasset, NY, USA, for providing access to previous immunochip genotyping data for this study.
| Funders | Funder number |
|---|---|
| American College of Rheumatology Research and Education Foundation Within Our Reach Rheumatoid Arthritis Translational Research | |
| UAB Center for Clinical and Translational Studies | 5UL1 RR025777-03 |
| National Institutes of Health (NIH) | K23 AR62100, UL1RR025777, 2P60 AR048095-06, K01 AR060848, N01 AR-6-2278 |
| National Center for Advancing Translational Sciences (NCATS) | UL1TR001417 |
ASJC Scopus subject areas
- Immunology
- Genetics
- Genetics(clinical)